[go: up one dir, main page]

WO2022035003A1 - Composition pharmaceutique comprenant du dutastéride - Google Patents

Composition pharmaceutique comprenant du dutastéride Download PDF

Info

Publication number
WO2022035003A1
WO2022035003A1 PCT/KR2021/000416 KR2021000416W WO2022035003A1 WO 2022035003 A1 WO2022035003 A1 WO 2022035003A1 KR 2021000416 W KR2021000416 W KR 2021000416W WO 2022035003 A1 WO2022035003 A1 WO 2022035003A1
Authority
WO
WIPO (PCT)
Prior art keywords
dutasteride
present
propylene glycol
composition
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/000416
Other languages
English (en)
Korean (ko)
Inventor
이진교
신형수
김정아
손수빈
김상동
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phil International Co Ltd
Original Assignee
Phil International Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phil International Co Ltd filed Critical Phil International Co Ltd
Publication of WO2022035003A1 publication Critical patent/WO2022035003A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising dutasteride, specifically dutasteride, including glycerol monocaprylocaprate and propylene glycol monocaprylate, and glycerol monocaprylocaprate and propylene glycol monocaprylate.
  • the present invention relates to a pharmaceutical composition having a weight ratio of prilate of 9: 1 to 6: 4, a capsule formulation comprising the composition, and a method of formulating the capsule formulation.
  • Dutasteride is a drug that suppresses androgens, a male hormone, and is used to treat benign prostatic hyperplasia and androgenetic alopecia.
  • Avodart (AVODART) is widely used in the market under the trade name, and this Avodart is an oblong soft capsule formulation with a long axis of about 19.1 mm, a short axis of about 6.7 mm, and a content weight of about 380 mg. Since dutasteride is poorly soluble, a large amount of oil is used to dissolve it, so the size of the dosage form is large, and accordingly, there is a problem that the medication compliance is low.
  • Korean Patent Registration No. 10-1679380 discloses that the capsule content contains 84.0% by weight or more of propylene glycol monolaurate and a surfactant having an HLB value of 10 or more to increase the solubility of dutasteride and capsules A method for improving medication compliance by reducing the size is suggested.
  • a surfactant with a high HLB value is used, there is a possibility that disintegration delay and dissolution rate decrease due to crosslinking due to reaction with gelatin, which is a capsule base, over time.
  • propylene glycol monolaurate containing 84.0% by weight or more in the above method is a relatively expensive oil, there is a problem in that the unit price of the product is increased.
  • Korean Patent Registration No. 10-1833280 discloses a method of improving stability by including a surfactant in the contents to solubilize dutasteride and using succinylated gelatin and crosslinking inhibitors (glycine and citric acid) as a capsule film is presenting
  • succinylated gelatin and crosslinking inhibitors glycine and citric acid
  • the present inventors can improve the solubility of dutasteride without including a surfactant, particularly a surfactant with a high HLB value, in order to overcome the problems of the prior art as described above, and use a relatively low cost raw material.
  • the main object of the present invention is to provide a pharmaceutical composition that can stably contain dutasteride at a high concentration without including a surfactant, particularly a surfactant having a high HLB value, and can be easily prepared at a low unit cost. there is.
  • Another object of the present invention is to provide a capsule formulation capable of improving the medication compliance using the composition.
  • Another object of the present invention is to provide a formulation method that can be easily carried out through a simple process as a method for preparing the capsule formulation as described above.
  • the present invention includes dutasteride, glycerol monocaprylocaprate and propylene glycol monocaprylate, and the weight ratio of glycerol monocaprylocaprate and propylene glycol monocaprylate is 9: 1 to 6: 4 pharmaceutical compositions are provided.
  • dutasteride in an amount of 0.1 to 1% by weight.
  • composition of the present invention it is preferable not to contain a surfactant having an HLB value of 6 or more.
  • composition of the present invention it is preferable to further include an antioxidant.
  • the present invention provides a capsule formulation comprising the pharmaceutical composition.
  • the film is made of a film containing gelatin succinate.
  • the present invention includes dutasteride, glycerol monocaprylocaprate and propylene glycol monocaprylate, wherein the weight ratio of glycerol monocaprylocaprate and propylene glycol monocaprylate is 9 : 1 to 6: 4 to prepare the capsule contents; and encapsulating the capsule contents with a succinate gelatin-containing film; provides a formulation method comprising.
  • the capsule contents by including dutasteride in an amount of 0.1 to 1% by weight.
  • the capsule contents without including a surfactant having an HLB value of 6 or more.
  • the pharmaceutical composition of the present invention can stably contain dutasteride at a high concentration without including a separate surfactant, and can be easily prepared at a low cost.
  • the dosage form of the present invention contains such a pharmaceutical composition and contains dutasteride at a high concentration, but it can be made to have a small size or to contain a large amount of dutasteride in one dosage form, so that medication compliance can be improved. .
  • 1 is a chemical structure of dutasteride.
  • Figure 2 shows the solubility of dutasteride according to the composition ratio of glycerol monocaprylocaprate (Capmul MCM) and propylene glycol monocaprylate (Capryol 90).
  • Figure 3 is a comparison showing the dissolution aspect of the capsule and Avodart capsule according to an embodiment of the present invention.
  • composition of the present invention includes dutasteride, glycerol monocaprylocaprate and propylene glycol monocaprylate, and the weight ratio of glycerol monocaprylocaprate and propylene glycol monocaprylate is 9: 1 to 6: 4 characterized in that
  • dutasteride is a compound having the chemical structure of FIG. 1 .
  • glycerol monocaprylocaprate is preferably a type 1 glycerol monocaprylocaprate of the European Pharmacopeia (EP) standard, and more preferably, Capmul MCM.
  • EP European Pharmacopeia
  • the propylene glycol monocaprylate (propylene glycol monocaprylate) is preferably a type 2 propylene glycol monocaprylate of the United States Pharmacopeia (USP) standard, and more preferably capryol 90 (Capryol 90) am.
  • USP United States Pharmacopeia
  • composition of the present invention preferably comprises 0.1 to 1% by weight of dutasteride.
  • composition of the present invention preferably contains 50 to 99.9% by weight of glycerol monocaprylocaprate and propylene glycol monocaprylate, more preferably 60 to 99.9%, more preferably 70 to 99.9%, More preferably, it contains 80 to 99.9%.
  • the weight ratio of glycerol monocaprylocaprate and propylene glycol monocaprylate is preferably 8:2 to 7:3.
  • composition of the present invention may consist of only the above components, that is, dutasteride, glycerol monocaprylocaprate and propylene glycol monocaprylate, and may further include other components in addition to these components.
  • additional ingredients may include other drugs other than dutasteride, auxiliary ingredients for stabilizing or delivering the drug, and other pharmaceutically acceptable additives.
  • it further comprises an antioxidant.
  • the antioxidant for example, butylhydroxytoluene may be used.
  • composition of the present invention may further include additional oils or surfactants in addition to the glycerol monocaprylocaprate and propylene glycol monocaprylate.
  • additional oils or surfactants are not included in addition to the glycerol monocaprylocaprate and propylene glycol monocaprylate.
  • the composition of the present invention may be a composition for various uses requiring the medicinal effect of dutasteride. Since dutasteride can inhibit androgens, which are male hormones, it can be used for the prevention, treatment or improvement of androgenetic alopecia or benign prostatic hyperplasia. Therefore, the composition of the present invention may be a composition for use as described above, that is, for preventing, treating or improving androgenetic alopecia or benign prostatic hyperplasia. In addition, it may be a composition for other uses requiring the medicinal effect of dutasteride.
  • composition of the present invention may be a composition for dutasteride capsule formulation.
  • composition for soft capsule formulation is a composition for soft capsule formulation.
  • the capsule formulation of the present invention is characterized in that it comprises the above composition.
  • the capsule formulation of the present invention is preferably a soft capsule formulation, and more preferably a soft capsule formulation comprising a film containing succinate gelatin.
  • the capsule formulation of the present invention can be used for various purposes requiring the medicinal effect of dutasteride.
  • it can be used for the above-mentioned uses, that is, the prevention, treatment or improvement of androgenetic alopecia or benign prostatic hyperplasia, or other uses requiring the medicinal effect of dutasteride.
  • the amount of the composition included in the capsule formulation of the present invention is not particularly limited, and may be appropriately set according to the use of the capsule formulation.
  • the capsule formulation of the present invention may contain 50 to 200 mg of the composition of the present invention per one capsule, but is not limited thereto.
  • composition and capsule formulation of the present invention may be administered to a subject in an appropriate amount according to each use as described above based on the content of dutasteride contained.
  • the dosage of dutasteride related thereto is well known in the art, and may be administered to the subject in various ranges depending on the subject's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and the severity of the disease. will be able
  • the formulation method of the present invention is a method that can be formulated into a capsule formulation as described above, and includes dutasteride, glycerol monocaprylocaprate and propylene glycol monocaprylate, glycerol monocaprylocaprate and propylene glycol preparing capsule contents by weight ratio of monocaprylate to 9: 1 to 6: 4; and encapsulating the capsule contents with a succinate gelatin-containing film.
  • dutasteride is included in an amount of 0.1 to 1% by weight to prepare the capsule contents.
  • the capsule content is prepared by including 50 to 99.9% by weight of glycerol monocaprylocaprate and propylene glycol monocaprylate, more preferably 60 to 99.9%, more Preferably 70 to 99.9%, more preferably 80 to 99.9% to prepare the capsule contents.
  • the weight ratio of glycerol monocaprylocaprate and propylene glycol monocaprylate is preferably 8: 2 to 7: 3 in the formulation method of the present invention.
  • the capsule contents can be prepared by including only dutasteride, glycerol monocaprylocaprate and propylene glycol monocaprylate, and the capsule contents can be prepared by further including other components in addition to these components.
  • additional ingredients may include other drugs other than dutasteride, auxiliary ingredients for stabilizing or delivering the drug, and other pharmaceutically acceptable additives.
  • an antioxidant is further included. In this case, as the antioxidant, for example, butylhydroxytoluene may be used.
  • the capsule contents may be prepared by further including additional oils or surfactants in addition to the glycerol monocaprylocaprate and propylene glycol monocaprylate.
  • the capsule content does not contain a surfactant having an HLB value of 6 or more, and preferably does not contain propylene glycol monolaurate. More preferably, the capsule content does not contain additional oils or surfactants other than the glycerol monocaprylocaprate and propylene glycol monocaprylate.
  • Korean Patent Registration No. 10-1679380 which was developed to improve the medication compliance of dutasteride formulation, that is, Avodart, contains 84 wt% or more of propylene glycol monolaurate in the composition (capsule contents), and the unit price of this oil is Since it is about twice as high as glycerol monocaprylocaprate used in Avodart, there is a problem in that the unit price of the formulation increases.
  • Capmul MCM a glycerol monocaprylocaprate
  • Lauroglycol FCC a type 1 propylene glycol monolaurate
  • the second Lauroglycol 90 a type of propylene glycol monolaurate
  • the unit price of propylene glycol monocaprylate used in the present invention is also similar to that of propylene glycol monolaurate.
  • Capryol PGMC a type 1 propylene glycol monocaprylate
  • Capryol 90 a type 2 propylene glycol monocaprylate
  • this oil is used less and mainly glycerol monocaprylocaprate having a low unit price is used, there is an advantage that the unit price can be lowered while improving the medication compliance.
  • 'Capmul MCM' was used as glycerol monocaprylocaprate, and 'Capryol 90' was used as propylene glycol monocaprylate.
  • Dutasteride Capmul MCM Capryol 90 Experimental group 1 0.3 20 0 Experimental group 2 0.3 18 2 Experimental group 3 0.3 16 4 Experimental group 4 0.3 14 6 Experimental group 5 0.3 12 8 Experimental group 6 0.3 10 10 Experimental group 7 0.3 8 12 Experimental group 8 0.3 6 14 Experimental group 9 0.3 4 16 Experimental group 10 0.3 2 18 Experimental group 11 0.3 0 20
  • composition 1 composition 2 composition 3
  • Dutasteride 0.5 0.5 0.5 0.5 Glycerol Monocaprylocaprate 71.465 83.465 95.465
  • Propylene glycol monocaprylate 48 36
  • Butylhydroxytoluene 0.035 0.035 0.035
  • the film was prepared using succinate gelatin and a plasticizer in the composition shown in Table 4 below, and then soft capsules were manufactured using a rotary automatic filling molding machine.
  • composition 1 Composition 2 composition 3
  • Dutasteride 0.5 mg 0.5 mg 0.5 mg Glycerol Monocaprylocaprate 71.465 mg 83.465 mg 95.465 mg
  • Propylene glycol monocaprylate 48 mg 36 mg 24 mg
  • Butylhydroxytoluene 0.035 mg 0.035 mg 0.035 mg content weight 120 mg 1 capsule total weight 230 mg capsule size 2
  • Experimental group 12 Experimental group 13
  • Experimental group 14 Dutasteride 0.5 g 0.5 g 0.5 g Glycerol Monocaprylocaprate 111.5 g 75.5 g - Propylene glycol monocaprylate - 36 g 111.5 g 30% hydrogen peroxide (H 2 O 2 ) 8 g 8 g 8 g
  • Experimental group 12 Experimental group 13
  • Experimental group 14 Early does not exist does not exist does not exist does not exist 3 days 0.13% does not exist does not exist 1 week 0.26% does not exist does not exist 2 weeks 1.34% 0.58% 0.19%
  • Test method Korean Pharmacopoeia dissolution test method 2 (paddle method)
  • Test solution 900 ml of 0.1N hydrochloric acid solution containing 2% sodium lauryl sulfate
  • the capsule formulation of the present invention exhibited a dissolution pattern similar to that of the existing Avodart capsule.
  • Dissolution test result of Avodart capsule 5 minutes 10 minutes 15 minutes 30 minutes 45 minutes test 1 2.1 32.5 70.9 97.2 97.4 test 2 25.4 48.3 73.3 79.8 101.8 test 3 2.1 34.2 50.3 90.4 92.6 test 4 2.1 44.5 87.5 88.2 92.4 test 5 2.1 47.6 83.4 94.3 95.2 test 6 2.4 45.3 79.0 95.4 96.3 Average 6.0 42.1 74.1 90.9 96.0 Standard Deviation 9.5 6.9 13.2 6.4 3.5
  • Dissolution test result of the capsule of the present invention 5 minutes 10 minutes 15 minutes 30 minutes 45 minutes test 1 0.5 38.4 78.4 93.8 94.9 test 2 1.2 25.3 74.3 95.4 95.9 test 3 1.1 31.2 77.0 91.8 94.3 test 4 0.8 26.6 78.2 92.9 96.3 test 5 1.3 34.2 87.7 93.6 93.9 test 6 0.4 36.8 68.1 93.4 94.7 Average 0.9 32.1 77.3 93.5 95.0 Standard Deviation 0.4 5.4 6.4 1.2 0.9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à une composition pharmaceutique, comprenant du dutastéride, et plus particulièrement : à une composition pharmaceutique comprenant du dutastéride, du monocaprylocaprate de glycérol et du monocaprylate de propylène glycol, le rapport pondéral du monocaprylocaprate de glycérol au monocaprylate de propylène glycol étant de 9:1 à 6:4 ; à une formulation de capsule comprenant la composition ; et à un procédé de formulation de la formulation de capsule. La composition pharmaceutique de la présente invention peut contenir de manière stable du dutastéride à une concentration élevée même sans inclure de tensioactif séparé, et peut être facilement préparée à un prix unitaire bas. En contenant une telle composition pharmaceutique, la formulation de la présente invention peut présenter une petite taille tout en contenant du dutastéride à une concentration élevée, ou peut contenir une grande quantité de dutastéride dans une formulation, et peut ainsi améliorer l'observance de la médication. De plus, le procédé de formulation de la présente invention peut être utilisé pour préparer d'excellentes formulations de dutastéride telles que décrites ci-dessus par un procédé simple.
PCT/KR2021/000416 2020-08-14 2021-01-12 Composition pharmaceutique comprenant du dutastéride Ceased WO2022035003A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0102523 2020-08-14
KR1020200102523A KR102199667B1 (ko) 2020-08-14 2020-08-14 두타스테리드를 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
WO2022035003A1 true WO2022035003A1 (fr) 2022-02-17

Family

ID=74126696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/000416 Ceased WO2022035003A1 (fr) 2020-08-14 2021-01-12 Composition pharmaceutique comprenant du dutastéride

Country Status (2)

Country Link
KR (1) KR102199667B1 (fr)
WO (1) WO2022035003A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102199667B1 (ko) * 2020-08-14 2021-01-07 (주)필인터내셔널 두타스테리드를 포함하는 약학적 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050024314A (ko) * 2002-06-05 2005-03-10 아이박스 파마슈티컬스 에스.알.오. 겔라틴 교차결합의 감소
WO2010092596A1 (fr) * 2009-02-10 2010-08-19 Genepharm India Private Limited Composition pharmaceutique orale de dutastéride
KR20150002446A (ko) * 2013-06-28 2015-01-07 한미약품 주식회사 두타스테라이드를 포함하는 경구용 연질 캡슐 제형
KR101716878B1 (ko) * 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
KR20190132926A (ko) * 2018-05-21 2019-11-29 (주)인벤티지랩 두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
KR20200023473A (ko) * 2017-09-01 2020-03-04 제이더블유중외제약 주식회사 두타스테라이드를 포함하는 고형 제제 및 이의 제조방법
KR102199667B1 (ko) * 2020-08-14 2021-01-07 (주)필인터내셔널 두타스테리드를 포함하는 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101679380B1 (ko) 2015-09-10 2016-11-25 주식회사 유유제약 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050024314A (ko) * 2002-06-05 2005-03-10 아이박스 파마슈티컬스 에스.알.오. 겔라틴 교차결합의 감소
WO2010092596A1 (fr) * 2009-02-10 2010-08-19 Genepharm India Private Limited Composition pharmaceutique orale de dutastéride
KR20150002446A (ko) * 2013-06-28 2015-01-07 한미약품 주식회사 두타스테라이드를 포함하는 경구용 연질 캡슐 제형
KR101716878B1 (ko) * 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
KR20200023473A (ko) * 2017-09-01 2020-03-04 제이더블유중외제약 주식회사 두타스테라이드를 포함하는 고형 제제 및 이의 제조방법
KR20190132926A (ko) * 2018-05-21 2019-11-29 (주)인벤티지랩 두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
KR102199667B1 (ko) * 2020-08-14 2021-01-07 (주)필인터내셔널 두타스테리드를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
KR102199667B1 (ko) 2021-01-07

Similar Documents

Publication Publication Date Title
WO2017196148A1 (fr) Formulation composite de dutastéride et de tadalafil comprenant un dérivé d'ester d'acide gras de glycérol ou un dérivé d'ester d'acide gras de propylène glycol et formulation de capsule orale comprenant celle-ci
US5505961A (en) Gelatin capsules containing a highly concentrated acetaminophen solution
WO2017116190A1 (fr) Composition pharmaceutique comprenant du dutastéride et du monolaurate de propylène glycol, et son procédé de préparation
JPH07116021B2 (ja) 医薬品のカプセル化の簡易化
BG65291B1 (bg) Фармацевтичен състав, съдържащ омепразол
WO2015141897A1 (fr) Composition pharmaceutique liquide
WO2017043913A1 (fr) Composition pharmaceutique comprenant du dutastéride et formulation en gélule la comprenant
WO2019103373A2 (fr) Dispersion solide de dutastéride, son procédé de production et composition pharmaceutique en comprenant
CN113616614A (zh) 一种醋酸阿比特龙软胶囊及其制备方法
WO2022035003A1 (fr) Composition pharmaceutique comprenant du dutastéride
WO2019045501A1 (fr) Préparation solide comprenant du dutastéride et procédé de préparation associé
JPH0840880A (ja) 軟ゼラチンカプセル剤中のケトプロフエン溶液に基づく医薬製剤およびその調製法
CA1043260A (fr) Sels d'acides gras lipophiles et hydrosolubles comprenant des agents therapeutiques dotes d'une molecule d'azote tertiaire pouvant echanger des ions h+
WO2018062831A1 (fr) Formulation composite de capsule orale contenant du dutastéride et du tadalafil
US20140073670A1 (en) Pharmaceutical composition comprising fexofenadine
EP2255786A1 (fr) Composition automicroémulsionnante de mitotane
WO2021029631A1 (fr) Formulation intra-orale à désintégration rapide contenant un extrait d'huile de chanvre ou un extrait de poudre de chanvre comme matière première de la formulation
WO2021194280A1 (fr) Nouvelle formulation pharmaceutique à stabilité améliorée contenant du taxane, un sel pharmaceutiquement acceptable de celui-ci, ou un hydrate de celui-ci
WO2021133051A1 (fr) Microsphères comprenant du ropinirole, et composition d'injection les comprenant
WO2021145618A1 (fr) Composition pharmaceutique incluant de l'acide r-thioctique ou un sel pharmaceutiquement acceptable de celui-ci, de l'huile, et un auxiliaire de dispersion
WO2018182208A1 (fr) Préparation complexe contenant du bazédoxifène ou un sel pharmaceutiquement acceptable de celui-ci et du cholécalciférol ou un sel pharmaceutiquement acceptable de celui-ci
WO2019078512A1 (fr) Nouvelle préparation semi-solide de l'udénafil
WO2011031100A2 (fr) Hybride aripiprazole-bentonite-aea, composition pharmaceutique le contenant et son procédé de préparation
WO2015163689A1 (fr) Composition contenant le principe actif (i) et procédé pour préparer celle-ci
WO2010008135A1 (fr) Capsule molle orale d’acéclofénac ayant une stabilité améliorée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21856012

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21856012

Country of ref document: EP

Kind code of ref document: A1